Johnson & Johnson (NYSE:JNJ) Shares Sold by Prospera Financial Services Inc

Posted by Defense World Staff on May 15th, 2023

Prospera Financial Services Inc decreased its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 19.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,724 shares of the company’s stock after selling 12,847 shares during the period. Prospera Financial Services Inc’s holdings in Johnson & Johnson were worth $9,667,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. State Street Corp raised its position in Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after acquiring an additional 803,013 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after acquiring an additional 805,831 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after acquiring an additional 328,297 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Johnson & Johnson by 2.7% during the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock worth $1,919,726,000 after acquiring an additional 310,473 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on JNJ shares. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price for the company. Atlantic Securities lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. StockNews.com started coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, SVB Leerink lowered their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $160.78 on Monday. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company has a 50 day moving average price of $159.10 and a 200 day moving average price of $166.69. The firm has a market capitalization of $417.82 billion, a price-to-earnings ratio of 33.64, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. During the same quarter in the prior year, the business posted $2.67 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is presently 99.58%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.